Table 2.
Hazard ratio (HR) of meningioma in patients with prostatic hyperplasia and prostate carcinoma, according to ever use of different types of male hormone-interfering drugs, compared to never users
| Types of male-hormone interfering drugs | Risk time (person-years)* | Number of meningiomas* | HR† | (95% CI‡) |
|---|---|---|---|---|
| 5-α-Reductase-inhibitors | 359,428 | 99 | 1.01 | (0.80–1.26) |
| Finasteride | 299,454 | 77 | 0.94 | (0.74–1.21) |
| Dutasteride | 78,576 | 30 | 1.30 | (0.89–1.91) |
| LHRH-agonist | 5,109 | ˂5§ | 1.63 | (0.40–6.53) |
| Buserelin | 254 | 0 | — | |
| Leuprorelin | 741 | 0 | — | |
| Goserelin | 3,953 | ˂5§ | 2.05 | (0.51–8.21) |
| Triptorelin | 256 | 0 | — | |
| Steroidal antiandrogens | ||||
| Cyproterone | 6,141 | ˂5§ | 1.81 | (0.58–5.64) |
| Nonsteroidal antiandrogen | 15,751 | 6 | 1.43 | (0.64–3.21) |
| Flutamide | 6,548 | 0 | — | |
| Bicalutamide | 9,887 | 6 | 2.16 | (0.97–4.85) |
| Enzalutamide | 1 | 0 | — | |
| Nilutamide | 9 | 0 | — |
*Some patients were exposed to more than one type of drug, therefore the total numbers do not add.
†HR, hazard ratio.
‡CI, confidence interval.
§Due to Danish law it is not permitted to specify counts less than 5.